JETA Molecular is a biotechnology startup based in The Netherlands, founded in 2016. The company's mission is to enhance outcomes for transplant patients through the provision of high-quality medical devices. Jeta aims to introduce groundbreaking tests that offer top-tier solutions for post-transplant disease relapse surveillance, as well as for the monitoring of organ and stem cell transplant rejection. These innovative systems are poised to revolutionize the industry, leading to improved laboratory workflows, reduced per test costs, and ultimately, superior patient care and survival rates. Currently, there is no information available regarding the last investment and the involved investors.
There is no investment information
No recent news or press coverage available for JETA Molecular.
We care about your data, and we'd love to use cookies make your experience better.
